CD8 T cell independent immunity after single dose infection-treatment-vaccination (ITV) against Plasmodium yoelii

Vaccine

Volumn 32, Issue 4, 2014, Pages 483-491

  Doll, Katherine L ^a   Butler, Noah S ^b   Harty, John T ^a,c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

Antibodies; CD8 T cells; Plasmodium infections; Subpatent infection; Vaccination

Indexed keywords

CHLOROQUINE; SPOROZOITE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; MOUSE; NONHUMAN; PARASITE LOAD; PARASITEMIA; PLASMODIUM YOELII INFECTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; VACCINATION;

ANTIBODIES; B6; C57BL/6; CD8 T CELLS; CHLOROQUINE; CQ; GAP; GENETICALLY ATTENUATED PARASITES; INFECTION-TREATMENT VACCINATION; ITV; PLASMODIUM INFECTIONS; PLASMODIUM YOELII 17XNL; PY; RADIATION-ATTENUATED SPOROZOITES; RAS; RBC; RED BLOOD CELL; SUBPATENT INFECTION; VACCINATION;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIMALARIALS; CD8-POSITIVE T-LYMPHOCYTES; CHLOROQUINE; FEMALE; MALARIA; MALARIA VACCINES; MICE; MICE, INBRED C57BL; PARASITEMIA; PLASMODIUM YOELII; SPOROZOITES; VACCINES, ATTENUATED;

EID: 84891629974     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.11.058     Document Type: Article

References (38)

1. W.M.R. World Malaria Report 2010 2010.
2. Hoffman S.L., Goh L.M., Luke T.C., Schneider I., Le T.P., Doolan D.L., et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 2002, 185(April (8)):1155-1164.
3. Roestenberg M., Bijker E.M., Sim B.K., Billingsley P.F., James E.R., Bastiaens G.J., et al. Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg 2013, 88(January (1)):5-13.
4. Belnoue E., Costa F.T., Frankenberg T., Vigario A.M., Voza T., Leroy N., et al. Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J Immunol 2004, 172(February (4)):2487-2495.
5. Beaudoin R.L., Strome C.P., Mitchell F., Tubergen T.A. Plasmodium berghei: immunization of mice against the ANKA strain using the unaltered sporozoite as an antigen. Exp Parasitol 1977, 42(June (1)):1-5.
6. Golenser J., Heeren J., Verhave J.P., Kaay H.J., Meuwissen J.H. Crossreactivity with sporozoites, exoerythrocytic forms and blood schizonts of Plasmodium berghei in indirect fluorescent antibody tests with sera of rats immunized with sporozoites or infected blood. Clin Exp Immunol 1977, 29(July (1)):43-51.
7. Orjih A.U., Cochrane A.H., Nussenzweig R.S. Comparative studies on the immunogenicity of infective and attenuated sporozoites of Plasmodium berghei. Trans R Soc Trop Med Hyg 1982, 76(1):57-61.
8. Roestenberg M., McCall M., Hopman J., Wiersma J., Luty A.J., van Gemert G.J., et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 2009, 361(July (5)):468-477.
9. Bijker E.M., Bastiaens G.J., Teirlinck A.C., van Gemert G.J., Graumans W., van de Vegte-Bolmer M., et al. Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc Natl Acad Sci U S A 2013, (April).
10. Schmidt N.W., Butler N.S., Badovinac V.P., Harty J.T. Extreme CD8T cell requirements for anti-malarial liver-stage immunity following immunization with radiation attenuated sporozoites. PLoS Pathog 2010, 6(7):e1000998.
11. Nganou-Makamdop K., van Gemert G.J., Arens T., Hermsen C.C., Sauerwein R.W. Long term protection after immunization with P. berghei sporozoites correlates with sustained IFNgamma responses of hepatic CD8+ memory T cells. PLoS ONE 2012, 7(5):e36508.
12. Butler N.S., Schmidt N.W., Vaughan A.M., Aly A.S., Kappe S.H., Harty J.T. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe 2011, 9(June (6)):451-462.
13. Doolan D.L., Hoffman S.L. The complexity of protective immunity against liver-stage malaria. J Immunol 2000, 165(August (3)):1453-1462.
14. Fink E. Assessment of causal prophylactic activity in Plasmodium berghei yoelii and its value for the development of new antimalarial drugs. Bull World Health Organ 1974, 50(3/4):213-222.
15. Wojciechowski W., Harris D.P., Sprague F., Mousseau B., Makris M., Kusser K., et al. Cytokine-producing effector B cells regulate type 2 immunity to H. polygyrus. Immunity 2009, 30(March (3)):421-433.
16. Doll K.L., Butler N.S., Harty J.T. Tracking the total CD8T cell response following whole Plasmodium vaccination. Methods Mol Biol 2013, 923:493-504.
17. Rai D., Pham N.L., Harty J.T., Badovinac V.P. Tracking the total CD8T cell response to infection reveals substantial discordance in magnitude and kinetics between inbred and outbred hosts. J Immunol 2009, 183(December (12)):7672-7681.
18. Amante F.H., Engwerda C.R., Good M.F. Experimental asexual blood stage malaria immunity. Curr Protoc Immunol 2011, (April). Chapter 19:Unit 19.4.
19. Bruna-Romero O., Hafalla J.C., Gonzalez-Aseguinolaza G., Sano G., Tsuji M., Zavala F. Detection of malaria liver-stages in mice infected through the bite of a single Anopheles mosquito using a highly sensitive real-time PCR. Int J Parasitol 2001, 31(November (13)):1499-1502.
20. Chattopadhyay R., Conteh S., Li M., James E.R., Epstein J.E., Hoffman S.L. The effects of radiation on the safety and protective efficacy of an attenuated Plasmodium yoelii sporozoite malaria vaccine. Vaccine 2009, 27(June (27)):3675-3680.
21. Doolan D.L., Hoffman S.L. IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model. J Immunol 1999, 163(July (2)):884-892.
22. Khan Z.M., Vanderberg J.P. Specific inflammatory cell infiltration of hepatic schizonts in BALB/c mice immunized with attenuated Plasmodium yoelii sporozoites. Int Immunol 1992, 4(July (7)):711-718.
23. Kumar K.A., Baxter P., Tarun A.S., Kappe S.H., Nussenzweig V. Conserved protective mechanisms in radiation and genetically attenuated uis3(-) and uis4(-) Plasmodium sporozoites. PLoS ONE 2009, 4(2):e4480.
24. Labaied M., Harupa A., Dumpit R.F., Coppens I., Mikolajczak S.A., Kappe S.H. Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection. Infect Immun 2007, 75(August (8)):3758-3768.
25. Sedegah M., Weiss W.W., Hoffman S.L. Cross-protection between attenuated Plasmodium berghei and P. yoelii sporozoites. Parasite Immunol 2007, 29(11):559-565.
26. Tarun A.S., Dumpit R.F., Camargo N., Labaied M., Liu P., Takagi A., et al. Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells. J Infect Dis 2007, 196(August (4)):608-616.
27. Friesen J., Silvie O., Putrianti E.D., Hafalla J.C., Matuschewski K., Borrmann S. Natural immunization against malaria: causal prophylaxis with antibiotics. Sci Transl Med 2010, 2(July (40)):40ra9.
28. Pombo D.J., Lawrence G., Hirunpetcharat C., Rzepczyk C., Bryden M., Cloonan N., et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 2002, 360(August (9333)):610-617.
29. Elliott S.R., Kuns R.D., Good M.F. Heterologous immunity in the absence of variant-specific antibodies after exposure to subpatent infection with blood-stage malaria. Infect Immun 2005, 73(April (4)):2478-2485.
30. Cohen S., Mc G.I., Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature 1961, 192(November):733-737.
31. Sabchareon A., Burnouf T., Ouattara D., Attanath P., Bouharoun-Tayoun H., Chantavanich P., et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 1991, 45(September (3)):297-308.
32. Butler N.S., Vaughan A.M., Harty J.T., Kappe S.H. Whole parasite vaccination approaches for prevention of malaria infection. Trends Immunol 2012, 33(May (5)):247-254.
33. Lau L.S., Fernandez Ruiz D., Davey G.M., de Koning-Ward T.F., Papenfuss A.T., Carbone F.R., et al. Blood-stage Plasmodium berghei infection generates a potent, specific CD8+ T-cell response despite residence largely in cells lacking MHC I processing machinery. J Infect Dis 2011, 204(December (12)):1989-1996.
34. Butler N.S., Moebius J., Pewe L.L., Traore B., Doumbo O.K., Tygrett L.T., et al. Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nat Immunol 2012, 13(February (2)):188-195.
35. Chinappi M., Via A., Marcatili P., Tramontano A. On the mechanism of chloroquine resistance in Plasmodium falciparum. PLoS ONE 2010, 5(11):e14064.
36. Wykes M.N., Kay J.G., Manderson A., Liu X.Q., Brown D.L., Richard D.J., et al. Rodent blood-stage Plasmodium survive in dendritic cells that infect naive mice. Proc Natl Acad Sci U S A 2011, 108(July (27)):11205-11210.
37. Clyde D.F. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg 1975, 24(May (3)):397-401.
38. Nussenzweig R.S., Vanderberg J., Most H., Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 1967, 216(October (5111)):160-162.